Recent updated data showed a trend towards an improved OS in favor of sunitinib, with almost 10 months median survival increase compared with placebo (38.6 vs. 29.1 months, HR 0.73; 95% CI 0.50–1.06, p = 0.094) [ 21 ].
← all excerpts
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).
1
—
—